Regulation of the Immune Cell Repertoire in Psoriasis Patients Upon Blockade of IL-17A or TNFα

Julia Tittes,Jennifer Brell,Pia Fritz,Constanze Jonak,Georg Stary,Julia M. Ressler,Sarojinidevi Künig,Wolfgang Weninger,Johannes Stöckl
DOI: https://doi.org/10.1007/s13555-024-01112-4
2024-03-10
Dermatology and Therapy
Abstract:Targeting of the proinflammatory cytokine interleukin 17A (IL-17A) or tumor necrosis factor alpha (TNFα) with the monoclonal antibodies (mAbs) ixekizumab or adalimumab, respectively, is a successful therapy for chronic plaque psoriasis. The effects of these treatments on immune cell populations in the skin are largely unknown.
dermatology
What problem does this paper attempt to address?